Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Leyland-Jones

Showing results (1-10 of 106) with videos related to

Pageof 11
Sort By:
Rational Drug Therapy|November 1, 1982
Hormones in cancerB Leyland-Jones
Seminars in Oncology|August 1, 1991
Pharmacokinetics and therapeutic index of gallium nitrateB Leyland-Jones
Oncology|November 6, 2001
Dose scheduling--HerceptinB Leyland-Jones
Seminars in Oncology|February 1, 1993
Targeted drug deliveryB Leyland-Jones
Anti-Cancer Drugs|May 7, 2002
Maximizing the response to Herceptin therapy through optimal use and patient selectionB Leyland-Jones
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Trastuzumab therapy for the metastatic patient: does the primary match?B Leyland-Jones
Journal of the National Cancer Institute|November 16, 1988
Whither the modulation of platinum?B Leyland-Jones
Pharmacology & Therapeutics|January 1, 1989
Enhancement of the antitumor activity of 5-fluorouracil by uridine rescueP Klubes, B Leyland-Jones
British Journal of Cancer|July 31, 2008
Promises and caveats of in silico biomarker discoveryL Pusztai, B Leyland-Jones
Oncology|November 6, 2001
Role of Herceptin in primary breast cancer: views from North America and EuropeB Leyland-Jones, I Smith
Pageof 11

Showing results (1-10 of 106) with videos related to

Sort By:
Pageof 11
Rational Drug Therapy|November 1, 1982
Hormones in cancerB Leyland-Jones
Seminars in Oncology|August 1, 1991
Pharmacokinetics and therapeutic index of gallium nitrateB Leyland-Jones
Oncology|November 6, 2001
Dose scheduling--HerceptinB Leyland-Jones
Seminars in Oncology|February 1, 1993
Targeted drug deliveryB Leyland-Jones
Anti-Cancer Drugs|May 7, 2002
Maximizing the response to Herceptin therapy through optimal use and patient selectionB Leyland-Jones
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 15, 2002
Trastuzumab therapy for the metastatic patient: does the primary match?B Leyland-Jones
Journal of the National Cancer Institute|November 16, 1988
Whither the modulation of platinum?B Leyland-Jones
Pharmacology & Therapeutics|January 1, 1989
Enhancement of the antitumor activity of 5-fluorouracil by uridine rescueP Klubes, B Leyland-Jones
British Journal of Cancer|July 31, 2008
Promises and caveats of in silico biomarker discoveryL Pusztai, B Leyland-Jones
Oncology|November 6, 2001
Role of Herceptin in primary breast cancer: views from North America and EuropeB Leyland-Jones, I Smith
Pageof 11